Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of “Moderate Buy” by Brokerages

Viking Therapeutics, Inc. (NASDAQ:VKTX) has earned a consensus rating of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $86.4167.

VKTX has been the subject of several analyst reports. BTIG Research reissued a “buy” rating and set a $125.00 price target on shares of Viking Therapeutics in a research report on Monday, September 22nd. Raymond James Financial decreased their price objective on shares of Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a research report on Thursday, July 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Wednesday. Citigroup raised their price target on shares of Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Finally, HC Wainwright reissued a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a research report on Monday, September 29th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in shares of Viking Therapeutics by 9,209.9% during the 1st quarter. GAMMA Investing LLC now owns 24,392 shares of the biotechnology company’s stock valued at $589,000 after purchasing an additional 24,130 shares in the last quarter. NBC Securities Inc. increased its stake in Viking Therapeutics by 222,100.0% during the 1st quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company’s stock worth $53,000 after buying an additional 2,221 shares in the last quarter. Wesbanco Bank Inc. increased its stake in Viking Therapeutics by 101.7% during the 1st quarter. Wesbanco Bank Inc. now owns 23,800 shares of the biotechnology company’s stock worth $575,000 after buying an additional 12,000 shares in the last quarter. Compagnie Lombard Odier SCmA increased its stake in Viking Therapeutics by 286.0% during the 1st quarter. Compagnie Lombard Odier SCmA now owns 20,245 shares of the biotechnology company’s stock worth $489,000 after buying an additional 15,000 shares in the last quarter. Finally, GSB Wealth Management LLC increased its stake in Viking Therapeutics by 12.2% during the 1st quarter. GSB Wealth Management LLC now owns 8,317 shares of the biotechnology company’s stock worth $201,000 after buying an additional 907 shares in the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Viking Therapeutics Price Performance

Shares of NASDAQ VKTX opened at $32.37 on Thursday. The stock has a market capitalization of $3.64 billion, a P/E ratio of -21.16 and a beta of 0.64. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.73. The business has a fifty day moving average price of $29.22 and a 200 day moving average price of $27.99.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.14). The firm’s revenue was up NaN% on a year-over-year basis. During the same quarter last year, the firm earned ($0.20) EPS. As a group, equities research analysts anticipate that Viking Therapeutics will post -1.56 earnings per share for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.